AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7630678
Drug: Stavudine (d4T)
RxNorm normalized name: STAVUDINE (d4T)
DrugBank: Stavudine (DB00649)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stavudine (d4T) at doses ranging from 0.125 to 4 mg/kg/day in two divided doses
Trial: 7630678
Drug: Prior zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prior zidovudine (ZDV) therapy
Trial: 2756920
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A capsules
Trial: 25968004
Drug: Internet-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive behavioural therapy (iCBT) program, completed over 10 weeks with six lessons.
Trial: 23783784
Drug: PLBs under
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PLBs under the guidance navigation system with a low-dose (LD) protocol
Trial: 19318446
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg oral DHEA/day
Trial: 17341993
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with valsartan and amlodipine
Trial: 15194584
Drug: Ibuprofen (2400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (2400 mg/day)
Trial: 15194584
Drug: Ibuprofen (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (in patients with knee swelling)
Trial: 9395946
Drug: Ordinary oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ordinary oxygen mask treatment (control group)
Trial: 3481307
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg furosemide plus 600 mg mofebutazone
Trial: 31098717
Drug: Neurogenic pain
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurogenic pain medication
Trial: 29512813
Drug: Quadratus Lumborum
RxNorm normalized name: Pisum quadratum whole
DrugBank: Pisum sativum whole (DB15545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadratus Lumborum Block type I with 24 mL 0.375% ropivacaine per side
Trial: 18946293
Drug: Sugammadex (4.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex (4.0 mg/kg)
Trial: 7408650
Drug: Thyroxine (50-150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyroxine (50-150 micrograms daily)
Trial: 31774566
Drug: F-652 (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F-652 (10, 30 or 45 μg/kg) administered on day-1 and 7
Trial: 26062182
Drug: Acupuncture to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture to restore consciousness combined with hyperbaric oxygen treatment
Trial: 26062182
Drug: Simple hyperbaric
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simple hyperbaric oxygen treatment
Trial: 21336131
Drug: alanine‐glutamine dipeptide‐supplemented
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alanine‐glutamine dipeptide‐supplemented total parenteral nutrition
Trial: 21336131
Drug: control total
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: control total parenteral nutrition
Trial: 17311603
Drug: Polyethylene glycol
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyethylene glycol laxative (17 g daily for 12 months)
Trial: 7836506
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist (buserelin, 500 micrograms/day s.c.)
Trial: 26855561
Drug: Nemonoxacin with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nemonoxacin with probenecid (1.5 g divided into three doses within 25 hours)
Trial: 26855561
Drug: Nemonoxacin with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nemonoxacin with cimetidine (400 mg thrice daily for 7 days)
Trial: 18341671
Drug: ivabradine 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ivabradine 10 mg b.i.d. for 4.5 days
Trial: 9773769
Drug: Mindfulness meditation-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness meditation-based stress reduction intervention (audiotaped instructions during light treatments)
Trial: 9773769
Drug: Control condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control condition (light treatments alone with no taped instructions)
Trial: 7522629
Drug: Chimeric anti-CD20
RxNorm normalized name: CHIMERIC ANTI-DISIALOGANGLIOSIDE (GD2) MONOCLONAL ANTIBODY (CH14.18/CHO)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) at doses of 10, 50, 100, 250, or 500 mg/m2
Trial: 7522629
Drug: Chimeric anti-CD20
RxNorm normalized name: CHIMERIC ANTI-DISIALOGANGLIOSIDE (GD2) MONOCLONAL ANTIBODY (CH14.18/CHO)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chimeric anti-CD20 monoclonal antibody (IDEC-C2B8)
Trial: 3122666
Drug: UFT 375
RxNorm normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT 375 mg/m2/day + MMC 5 mg/m2 for 1‐2 weeks
Trial: 3122666
Drug: UFT +
RxNorm normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT + ACNU 60 mg/m2/week for 2 weeks (with a 4-week interval)
Trial: 24570980
Drug: 5 ×
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 × 5 mm dental implants with a novel nanostructured calcium-incorporated titanium surface
Trial: 24570980
Drug: at least
RxNorm normalized name: Lovaza 1000 MG (at least 900 MG) Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: at least 10 mm long implants in augmented bone
Trial: 24570980
Drug: 5 ×
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 × 5 mm dental implants
Trial: 24570980
Drug: at least
RxNorm normalized name: Lovaza 1000 MG (at least 900 MG) Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: at least 10 mm long implants
Trial: 16940217
Drug: Sildenafil 50
RxNorm normalized name: sildenafil 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 50 mg, 3 times daily for 16 days
Trial: 9106924
Drug: Ialugen cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ialugen cream (hyaluronic acid)
Trial: 3705659
Drug: Telenzepine 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telenzepine 1 mg
Trial: 3653758
Drug: Telenzepine 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telenzepine 2 mg
Trial: 3653758
Drug: Telenzepine 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telenzepine 3 mg
Trial: 3653758
Drug: Telenzepine 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telenzepine 5 mg
Trial: 3705659
Drug: Telenzepine (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telenzepine (all doses)
Trial: 26620496
Drug: MK-5108 monotherapy
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-5108 monotherapy (Panel1) at doses ranging from 200 to 1800 mg, administered p.o. BID Q12h on days 1-2 in 14-21 day cycles.
Trial: 26620496
Drug: MK-5108 in
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-5108 in combination with docetaxel (Panel2) at 450 mg/day, administered IV docetaxel 60 mg/m2.
Trial: 22122738
Drug: Ablative fractional
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ablative fractional laser therapy (10,600-nm FLT, 10 mJ/microbeam, 35-45% coverage) for three to five sessions
Trial: 22122738
Drug: Nonablative fractional
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonablative fractional laser therapy (1,550-nm FLT, 15 mJ/microbeam, 14-20% coverage) for three to five sessions
Trial: 22122738
Drug: Topical bleaching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical bleaching
Trial: 19853332
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of glutamate
Trial: 3898832
Drug: Sucralfate (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate (900 mg before meals and at bedtime)
Trial: 31574879
Drug: Antimicrobial photodynamic
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial photodynamic therapy (aPDT) applied for the treatment of infected dentin, followed by restoration with high viscosity glass ionomer cement.
Trial: 28005265
Drug: tabalumab 100
RxNorm normalized name: Tabalumab
DrugBank: Tabalumab (DB11657)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tabalumab 100 mg
Trial: 28005265
Drug: tabalumab 300
RxNorm normalized name: Tabalumab
DrugBank: Tabalumab (DB11657)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tabalumab 300 mg
Trial: 24814500
Drug: Moderate dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate dose of LPS (0.8 ng/kg)
Trial: 24814500
Drug: Low-dose LPS
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose LPS (0.4 ng/kg)
Trial: 17582069
Drug: Estrogen therapy
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen therapy (0.625 mg per day)
Trial: 17582069
Drug: Estrogen therapy
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen therapy (with at least 80% adherence)
Trial: 10735926
Drug: Ranitidine bismuth
RxNorm normalized name: RANITIDINE BISMUTH CITRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine bismuth citrate (400 mg b.d.) with amoxycillin (1 g b.d.) and clarithromycin (500 mg b.d.)
Trial: 10735926
Drug: Omeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (20 mg b.d.) with amoxycillin (1 g b.d.) and clarithromycin (500 mg b.d.)
Trial: 9177359
Drug: Testosterone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone (200 mg testosterone cypionate biweekly for 12 months)
Trial: 1539524
Drug: Early initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Early initiation of warfarin (within 48 hours of heparin)
Trial: 1539524
Drug: Late initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Late initiation of warfarin (96 hours or later after heparin)
Trial: 24326799
Drug: Intravenous Ergometrine
RxNorm normalized name: Ergometrine
DrugBank: Ergometrine (DB01253)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Ergometrine
Trial: 23584366
Drug: Modified-release prednisone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified-release prednisone (MR-pred) 5 mg/day
Trial: 10979160
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment tailored to individual symptoms and standardized component for health and immune function
Trial: 8971289
Drug: fedotozine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fedotozine (30 mg t.d.s.)
Trial: 1593505
Drug: Cognitive-behavioural problem
RxNorm normalized name: Psoriasin Problem Skin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioural problem solving treatment
Trial: 30426300
Drug: ATP (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATP (160 mcg/kg/min)
Trial: 30426300
Drug: Adenosine (140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenosine (140 mcg/kg/min)
Trial: 21071171
Drug: Standard occupational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard occupational therapy (SOT)
Trial: 19898595
Drug: Esomeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole (20 mg VO e/12h) with Amoxicillin (1g VO e/12h) and Clarithromycin (500 mg VO e/12h)
Trial: 19898595
Drug: Omeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (20 mg VO e/12h) with Amoxicillin (1g VO e/12h) and Clarithromycin (500 mg VO e/12h)
Trial: 17767050
Drug: Lymphoplasmapheresis (LPE)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lymphoplasmapheresis (LPE) in addition to medical treatment
Trial: 12101789
Drug: Metoprolol (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (initial dose of 15 mg intravenously, followed by 100 mg/d orally)
Trial: 12101789
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no metoprolol administered)
Trial: 11225795
Drug: cHUT drug-free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cHUT drug-free phase
Trial: 2080948
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of co-dergocrine mesilate and nifedipine (Pontuc)
Trial: 469515
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of L‐tryptophan
Trial: 469515
Drug: 1/4 g
RxNorm normalized name: THYROID 15-16MG (1/4 GR) CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1/4 g of L‐tryptophan
Trial: 469515
Drug: 1/2 g
RxNorm normalized name: Thyroid 1/2 Grain (30mg) Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1/2 g of L‐tryptophan
Trial: 30791804
Drug: sifalimumab (IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sifalimumab (IV 1.0, 3.0, and 10.0 mg/kg or subcutaneous 100 mg every 2 weeks; IV 600 and 1200 mg every 6 weeks)
Trial: 30791804
Drug: sifalimumab (same
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sifalimumab (same doses as Stage I or 600 mg IV every 4 weeks if enrolled later)
Trial: 28137336
Drug: 8-week group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8-week group Cognitive Behavioural Therapy for perfectionism (CBT-P)
Trial: 19395071
Drug: Postoperative morphine-bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative morphine-bupivacaine PCEA
Trial: 19395071
Drug: Postoperative intravenous
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative intravenous morphine PCA
Trial: 9284850
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg single dose of sertraline (after a single dose of desipramine)
Trial: 9284850
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg single dose of sertraline (after multiple doses of desipramine)
Trial: 9284850
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg single dose of sertraline (after a single dose of imipramine)
Trial: 9284850
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg single dose of sertraline (after multiple doses of imipramine)
Trial: 8511496
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg famotidine twice daily (group 1)
Trial: 8511496
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg famotidine twice daily (group 2)
Trial: 8511496
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg ranitidine twice daily (group 3)
Trial: 29113986
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg MPX (low dose)
Trial: 29113986
Drug: 4,000 mg
RxNorm normalized name: lysine acetate 4,000 mg ORAL POWDER IN PACKET (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4,000 mg MPX (high dose)
Trial: 29113986
Drug: MPX (pooled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPX (pooled treatment arms) in SOD2 Alanine/Alanine genotype patients
Trial: 27827328
Drug: Intra-arterial treatment
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial treatment in high CBS group
Trial: 24726142
Drug: Neoadjuvant sorafenib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant sorafenib treatment for 4 weeks before tumor nephrectomy
Trial: 20614124
Drug: Telmisartan 40/80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan 40/80 mg once daily
Trial: 20206670
Drug: 23-valent pneumococcal
RxNorm normalized name: Streptococcus pneumoniae type 1 capsular polysaccharide antigen
DrugBank: Streptococcus pneumoniae type 1 capsular polysaccharide antigen (DB10319)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 23-valent pneumococcal polysaccharide vaccine (23vPPS) at 12 months
Trial: 12094857
Drug: Balsalazide (2.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balsalazide (2.25 g daily)
Trial: 12094857
Drug: Mesalamine (2.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesalamine (2.4 g daily)
Trial: 10379633
Drug: moexipril 15
RxNorm normalized name: moexipril 15 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: moexipril 15 mg once daily
Trial: 10379633
Drug: nitrendipine 20
RxNorm normalized name: nitrendipine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nitrendipine 20 mg once daily
Trial: 9289465
Drug: Phenazone (18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenazone (18 mg/kg body mass) administered orally after surgical ovariectomy
Trial: 9289465
Drug: Phenazone (18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenazone (18 mg/kg body mass) administered orally before surgical ovariectomy
Trial: 6499895
Drug: Clonidine (CLON)
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clonidine (CLON) 0.2 mg daily
Trial: 6499895
Drug: Moxonidine (MOX)
DrugBank: Moxonidine (DB09242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxonidine (MOX) 0.2 mg daily
Trial: 16116971
Drug: CPA +
RxNorm normalized name: Cyproterone acetate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPA + metformin (n = 25)
Trial: 14503550
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy of corticosteroids and cytotoxic medications
Trial: 8672151
Drug: Multimodal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal therapy (chemotherapy and radiotherapy followed by surgery)
Trial: 1925820
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Nifedipine and Captopril)
Trial: 1925820
Drug: Nifedipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (10 mg) and Captopril (25 mg)
Trial: 6388722
Drug: BICAP bipolar
RxNorm normalized name: quetiapine
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BICAP bipolar electrocoagulation treatment
Trial: 30952032
Drug: CHORDATA® method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHORDATA® method (body suspension and pendulum exercises)
Trial: 26871851
Drug: Human urinary
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Human urinary kallidinogenase for 7 days, followed by maintenance therapy of pancreatic kallikrein for 6 months
Trial: 25144133
Drug: 6 mg·kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg·kg of caffeine (CAF)
Trial: 22331946
Drug: Weekly paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly paclitaxel (WP) 80 mg/m² for 12 weeks followed by FEC (fluorouracil 500 mg/m², epirubicin 100 mg/m², cyclophosphamide 500 mg/m²) every 3 weeks for four cycles
Trial: 22331946
Drug: Docetaxel (XT)
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel (XT) 75 mg/m² on day 1 and capecitabine (1,500 mg/m² on days 1 through 14) every 3 weeks for four cycles followed by FEC for four cycles
Trial: 22331946
Drug: Weekly paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly paclitaxel (WP)
Trial: 17959981
Drug: Oral pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral pregabalin 100 mg
Trial: 17321219
Drug: Randomized Play-the-Winner
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized Play-the-Winner (RPW) treatment allocation
Trial: 14722890
Drug: Aerosol administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerosol administration of Edmonston-Zagreb measles vaccine (10^3.6 pfu/dose)
Trial: 14722890
Drug: Subcutaneous administration
RxNorm normalized name: subcutaneous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous administration of Edmonston-Zagreb measles vaccine (10^4.27 pfu/dose)
Trial: 14722890
Drug: Aerosol administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerosol administration of Edmonston-Zagreb measles vaccine
Trial: 14722890
Drug: Subcutaneous administration
RxNorm normalized name: subcutaneous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous administration of Edmonston-Zagreb measles vaccine
Trial: 11288792
Drug: EMD +
RxNorm normalized name: Emdisterone
DrugBank: Drostanolone propionate (DB14655)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMD + AB (Enamel Matrix Proteins + Antibiotics)
Trial: 3521856
Drug: Desoximetasone gel
RxNorm normalized name: Desoximetasone Gel
DrugBank: Desoximetasone (DB00547)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desoximetasone gel 0.05%